Current Assets
Accounts Receivable
Gilead Sciences Accounts Receivable decreased by 6.0% to $5.54B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.5%, from $5.26B to $5.54B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows relatively stable performance with a 1.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 7, 2026
How to read this metric
Rapid growth relative to sales may indicate collection issues or aggressive revenue recognition; stability suggests efficient cash conversion.
Detailed definition
This represents the total amount owed to the company by customers for goods or services delivered, minus the allowance f...
Peer comparison
Standard metric for all companies with B2B or credit-based sales models.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.91B | $5.28B | $5.28B | $4.56B | $4.90B | $5.01B | $5.46B | $4.93B | $5.05B | $5.59B | $5.50B | $5.52B | $5.49B | $5.46B | $5.32B | $5.26B | $5.62B | $5.99B | $5.90B | $5.54B |
| QoQ Change | — | +7.7% | -0.1% | -13.6% | +7.5% | +2.1% | +9.1% | -9.7% | +2.4% | +10.6% | -1.6% | +0.4% | -0.6% | -0.4% | -2.6% | -1.2% | +7.0% | +6.6% | -1.7% | -6.0% |
| YoY Change | — | — | — | — | -0.1% | -5.3% | +3.5% | +8.2% | +3.0% | +11.6% | +0.6% | +11.9% | +8.7% | -2.2% | -3.2% | -4.8% | +2.5% | +9.7% | +10.8% | +5.5% |
Range$4.56B – $5.99B
CAGR+2.6%
Avg YoY Growth+3.8%
Median YoY Growth+3.3%
Current Streak2 quarters decline
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's accounts receivable?
- Gilead Sciences (GILD) reported accounts receivable of $5.54B in Q1 2026.
- How has Gilead Sciences's accounts receivable changed year-over-year?
- Gilead Sciences's accounts receivable increased by 5.5% year-over-year, from $5.26B to $5.54B.
- What is the long-term trend for Gilead Sciences's accounts receivable?
- Over 5 years (2020 to 2025), Gilead Sciences's accounts receivable has grown at a 1.2% compound annual growth rate (CAGR), from $5.56B to $5.90B.
- What does accounts receivable mean?
- The net amount of money owed by customers after accounting for potential non-payments.